APO Research
Talk to an analyst

APO RESEARCH · REPORT

Blood Plasma Derivatives

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Blood Plasma Derivatives Market Analysis and Forecast 2026-2032

21 December 2025200 pages

Choose your research edition.

Industry ResearchBlood Plasma Derivatives Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Blood Plasma Derivatives Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Blood Plasma Derivatives Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Blood Plasma Derivatives Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Blood Plasma Derivatives Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Blood Plasma Derivatives market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Blood Plasma Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Blood Plasma Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Blood Plasma Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Blood Plasma Derivatives is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Blood Plasma Derivatives include Yuanda Shuyang, Takeda, Weiguang Bio, Tiantan Bio, CBPO, Shuanglin Bio, RAAS, Nanyue Bio and Hualan Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Blood Plasma Derivatives, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Blood Plasma Derivatives, also provides the revenue of main regions and countries. Of the upcoming market potential for Blood Plasma Derivatives, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Blood Plasma Derivatives revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Blood Plasma Derivatives market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Blood Plasma Derivatives revenue, projected growth trends, production technology, application and end-user industry.

Blood Plasma Derivatives Segment by Company

Yuanda Shuyang

Takeda

Weiguang Bio

Tiantan Bio

CBPO

Shuanglin Bio

RAAS

Nanyue Bio

Hualan Bio

Boya Bio

Octapharma

LFB Group

KM Biologics

Kedrion

Grifols

CSL

BPL

Biotest

Blood Plasma Derivatives Segment by Type

Albumin

Coagulation Factor

Immune Globulin

Other

Blood Plasma Derivatives Segment by Application

Hospital

Retail Pharmacy

Other

Blood Plasma Derivatives Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Plasma Derivatives market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Blood Plasma Derivatives and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Plasma Derivatives.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Blood Plasma Derivatives in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Blood Plasma Derivatives company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Plasma Derivatives revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Blood Plasma Derivatives Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Albumin Major Player Table 3. Coagulation Factor Major Player Table 4. Immune Globulin Major Player Table 5. Other Major Player Table 6. Global Blood Plasma Derivatives Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Retail Pharmacy Major Player Table 9. Other Major Player Table 10. Blood Plasma Derivatives Industry Trends Table 11. Blood Plasma Derivatives Industry Drivers Table 12. Blood Plasma Derivatives Industry Opportunities and Challenges Table 13. Blood Plasma Derivatives Industry Restraints Table 14. Global Blood Plasma Derivatives Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Blood Plasma Derivatives Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Blood Plasma Derivatives Market Share by Region (2021-2026) Table 17. Global Blood Plasma Derivatives Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Blood Plasma Derivatives Market Share by Region (2027-2032) Table 19. Global Blood Plasma Derivatives Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Blood Plasma Derivatives Revenue Market Share by Players (2021-2026) Table 21. Global Blood Plasma Derivatives Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Blood Plasma Derivatives Key Players Headquarters & Area Served Table 23. Global Blood Plasma Derivatives Players, Product Type & Application Table 24. Global Blood Plasma Derivatives Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Blood Plasma Derivatives by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Blood Plasma Derivatives Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Blood Plasma Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Blood Plasma Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Blood Plasma Derivatives Revenue Market Share by Type (2021-2026) Table 31. Global Blood Plasma Derivatives Revenue Market Share by Type (2027-2032) Table 32. Global Blood Plasma Derivatives Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Blood Plasma Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Blood Plasma Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Blood Plasma Derivatives Revenue Market Share by Application (2021-2026) Table 36. Global Blood Plasma Derivatives Revenue Market Share by Application (2027-2032) Table 37. Yuanda Shuyang Company Information Table 38. Yuanda Shuyang Business Overview Table 39. Yuanda Shuyang Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Yuanda Shuyang Blood Plasma Derivatives Product Portfolio Table 41. Yuanda Shuyang Recent Development Table 42. Takeda Company Information Table 43. Takeda Business Overview Table 44. Takeda Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Takeda Blood Plasma Derivatives Product Portfolio Table 46. Takeda Recent Development Table 47. Weiguang Bio Company Information Table 48. Weiguang Bio Business Overview Table 49. Weiguang Bio Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Weiguang Bio Blood Plasma Derivatives Product Portfolio Table 51. Weiguang Bio Recent Development Table 52. Tiantan Bio Company Information Table 53. Tiantan Bio Business Overview Table 54. Tiantan Bio Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Tiantan Bio Blood Plasma Derivatives Product Portfolio Table 56. Tiantan Bio Recent Development Table 57. CBPO Company Information Table 58. CBPO Business Overview Table 59. CBPO Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. CBPO Blood Plasma Derivatives Product Portfolio Table 61. CBPO Recent Development Table 62. Shuanglin Bio Company Information Table 63. Shuanglin Bio Business Overview Table 64. Shuanglin Bio Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Shuanglin Bio Blood Plasma Derivatives Product Portfolio Table 66. Shuanglin Bio Recent Development Table 67. RAAS Company Information Table 68. RAAS Business Overview Table 69. RAAS Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. RAAS Blood Plasma Derivatives Product Portfolio Table 71. RAAS Recent Development Table 72. Nanyue Bio Company Information Table 73. Nanyue Bio Business Overview Table 74. Nanyue Bio Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Nanyue Bio Blood Plasma Derivatives Product Portfolio Table 76. Nanyue Bio Recent Development Table 77. Hualan Bio Company Information Table 78. Hualan Bio Business Overview Table 79. Hualan Bio Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Hualan Bio Blood Plasma Derivatives Product Portfolio Table 81. Hualan Bio Recent Development Table 82. Boya Bio Company Information Table 83. Boya Bio Business Overview Table 84. Boya Bio Blood Plasma Derivatives Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Boya Bio Blood Plasma Derivatives Product Portfolio Table 86. Boya Bio Recent Development Table 87. Octapharma Company Information Table 88. Octapharma Business Overview Table 89. Octapharma Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Octapharma Blood Plasma Derivatives Product Portfolio Table 91. Octapharma Recent Development Table 92. LFB Group Company Information Table 93. LFB Group Business Overview Table 94. LFB Group Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. LFB Group Blood Plasma Derivatives Product Portfolio Table 96. LFB Group Recent Development Table 97. KM Biologics Company Information Table 98. KM Biologics Business Overview Table 99. KM Biologics Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. KM Biologics Blood Plasma Derivatives Product Portfolio Table 101. KM Biologics Recent Development Table 102. Kedrion Company Information Table 103. Kedrion Business Overview Table 104. Kedrion Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Kedrion Blood Plasma Derivatives Product Portfolio Table 106. Kedrion Recent Development Table 107. Grifols Company Information Table 108. Grifols Business Overview Table 109. Grifols Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Grifols Blood Plasma Derivatives Product Portfolio Table 111. Grifols Recent Development Table 112. CSL Company Information Table 113. CSL Business Overview Table 114. CSL Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. CSL Blood Plasma Derivatives Product Portfolio Table 116. CSL Recent Development Table 117. BPL Company Information Table 118. BPL Business Overview Table 119. BPL Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. BPL Blood Plasma Derivatives Product Portfolio Table 121. BPL Recent Development Table 122. Biotest Company Information Table 123. Biotest Business Overview Table 124. Biotest Blood Plasma Derivatives Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Biotest Blood Plasma Derivatives Product Portfolio Table 126. Biotest Recent Development Table 127. North America Blood Plasma Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Blood Plasma Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Blood Plasma Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Blood Plasma Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Blood Plasma Derivatives Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Blood Plasma Derivatives Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Blood Plasma Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Blood Plasma Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Blood Plasma Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Blood Plasma Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Blood Plasma Derivatives Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Blood Plasma Derivatives Revenue by Country (US$ Million) & (2027-2032) Table 141. China Blood Plasma Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 142. China Blood Plasma Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 143. China Blood Plasma Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 144. China Blood Plasma Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Blood Plasma Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Blood Plasma Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Blood Plasma Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Blood Plasma Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Blood Plasma Derivatives Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Blood Plasma Derivatives Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Blood Plasma Derivatives Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Blood Plasma Derivatives Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Blood Plasma Derivatives Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Blood Plasma Derivatives Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Blood Plasma Derivatives Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Blood Plasma Derivatives Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Blood Plasma Derivatives Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Blood Plasma Derivatives Image Figure 2. Global Blood Plasma Derivatives Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Blood Plasma Derivatives Market Size Share 2021 VS 2025 VS 2032 Figure 4. Albumin Image Figure 5. Coagulation Factor Image Figure 6. Immune Globulin Image Figure 7. Other Image Figure 8. Global Blood Plasma Derivatives Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Blood Plasma Derivatives Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Retail Pharmacy Image Figure 12. Other Image Figure 13. Global Blood Plasma Derivatives Market Size (US$ Million) & (2021-2032) Figure 14. Global Blood Plasma Derivatives Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Blood Plasma Derivatives Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Blood Plasma Derivatives Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Blood Plasma Derivatives Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Blood Plasma Derivatives Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Blood Plasma Derivatives Revenue Market Share by Type (2021-2032) Figure 21. Global Blood Plasma Derivatives Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Blood Plasma Derivatives Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Blood Plasma Derivatives Revenue Market Share by Application (2021-2032) Figure 24. North America Blood Plasma Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Blood Plasma Derivatives Revenue Share by Type (2021-2032) Figure 26. North America Blood Plasma Derivatives Revenue Share by Application (2021-2032) Figure 27. North America Blood Plasma Derivatives Revenue Share by Country (2021-2032) Figure 28. United States Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Blood Plasma Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Blood Plasma Derivatives Revenue Share by Type (2021-2032) Figure 33. Europe Blood Plasma Derivatives Revenue Share by Application (2021-2032) Figure 34. Europe Blood Plasma Derivatives Revenue Share by Country (2021-2032) Figure 35. Germany Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Blood Plasma Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Blood Plasma Derivatives Revenue Share by Type (2021-2032) Figure 45. China Blood Plasma Derivatives Revenue Share by Application (2021-2032) Figure 46. Asia Blood Plasma Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Blood Plasma Derivatives Revenue Share by Type (2021-2032) Figure 48. Asia Blood Plasma Derivatives Revenue Share by Application (2021-2032) Figure 49. Asia Blood Plasma Derivatives Revenue Share by Region (2021-2032) Figure 50. Japan Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Blood Plasma Derivatives Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Blood Plasma Derivatives Revenue Share by Type (2021-2032) Figure 58. SAMEA Blood Plasma Derivatives Revenue Share by Application (2021-2032) Figure 59. SAMEA Blood Plasma Derivatives Revenue Share by Country (2021-2032) Figure 60. Brazil Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Blood Plasma Derivatives Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Albumin
  • Coagulation Factor
  • Immune Globulin
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Yuanda Shuyang
  • Takeda
  • Weiguang Bio
  • Tiantan Bio
  • CBPO
  • Shuanglin Bio
  • RAAS
  • Nanyue Bio
  • Hualan Bio
  • Boya Bio
  • Octapharma
  • LFB Group
  • KM Biologics
  • Kedrion
  • Grifols
  • CSL
  • BPL
  • Biotest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Blood Plasma Derivatives Market by Type
  3. 1.2.1 Global Blood Plasma Derivatives Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Albumin
  5. 1.2.3 Coagulation Factor
  6. 1.2.4 Immune Globulin
  7. 1.2.5 Other
  8. 1.3 Blood Plasma Derivatives Market by Application
  9. 1.3.1 Global Blood Plasma Derivatives Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Retail Pharmacy
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Blood Plasma Derivatives Market Dynamics
  1. 2.1 Blood Plasma Derivatives Industry Trends
  2. 2.2 Blood Plasma Derivatives Industry Drivers
  3. 2.3 Blood Plasma Derivatives Industry Opportunities and Challenges
  4. 2.4 Blood Plasma Derivatives Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Blood Plasma Derivatives Market Perspective (2021-2032)
  2. 3.2 Global Blood Plasma Derivatives Growth Trends by Region
  3. 3.2.1 Global Blood Plasma Derivatives Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Blood Plasma Derivatives Market Size by Region (2021-2026)
  5. 3.2.3 Global Blood Plasma Derivatives Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Blood Plasma Derivatives Revenue by Players
  2. 4.1.1 Global Blood Plasma Derivatives Revenue by Players (2021-2026)
  3. 4.1.2 Global Blood Plasma Derivatives Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Blood Plasma Derivatives Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Blood Plasma Derivatives Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Blood Plasma Derivatives Key Players Headquarters & Area Served
  7. 4.4 Global Blood Plasma Derivatives Players, Product Type & Application
  8. 4.5 Global Blood Plasma Derivatives Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Blood Plasma Derivatives Market CR5 and HHI
  11. 4.6.3 2025 Blood Plasma Derivatives Tier 1, Tier 2, and Tier 3
5 Blood Plasma Derivatives Market Size by Type
  1. 5.1 Global Blood Plasma Derivatives Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Blood Plasma Derivatives Revenue by Type (2021-2032)
  3. 5.3 Global Blood Plasma Derivatives Revenue Market Share by Type (2021-2032)
6 Blood Plasma Derivatives Market Size by Application
  1. 6.1 Global Blood Plasma Derivatives Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Blood Plasma Derivatives Revenue by Application (2021-2032)
  3. 6.3 Global Blood Plasma Derivatives Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Yuanda Shuyang
  2. 7.1.1 Yuanda Shuyang Company Information
  3. 7.1.2 Yuanda Shuyang Business Overview
  4. 7.1.3 Yuanda Shuyang Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Yuanda Shuyang Blood Plasma Derivatives Product Portfolio
  6. 7.1.5 Yuanda Shuyang Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Blood Plasma Derivatives Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Weiguang Bio
  14. 7.3.1 Weiguang Bio Company Information
  15. 7.3.2 Weiguang Bio Business Overview
  16. 7.3.3 Weiguang Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Weiguang Bio Blood Plasma Derivatives Product Portfolio
  18. 7.3.5 Weiguang Bio Recent Developments
  19. 7.4 Tiantan Bio
  20. 7.4.1 Tiantan Bio Company Information
  21. 7.4.2 Tiantan Bio Business Overview
  22. 7.4.3 Tiantan Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Tiantan Bio Blood Plasma Derivatives Product Portfolio
  24. 7.4.5 Tiantan Bio Recent Developments
  25. 7.5 CBPO
  26. 7.5.1 CBPO Company Information
  27. 7.5.2 CBPO Business Overview
  28. 7.5.3 CBPO Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  29. 7.5.4 CBPO Blood Plasma Derivatives Product Portfolio
  30. 7.5.5 CBPO Recent Developments
  31. 7.6 Shuanglin Bio
  32. 7.6.1 Shuanglin Bio Company Information
  33. 7.6.2 Shuanglin Bio Business Overview
  34. 7.6.3 Shuanglin Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Shuanglin Bio Blood Plasma Derivatives Product Portfolio
  36. 7.6.5 Shuanglin Bio Recent Developments
  37. 7.7 RAAS
  38. 7.7.1 RAAS Company Information
  39. 7.7.2 RAAS Business Overview
  40. 7.7.3 RAAS Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  41. 7.7.4 RAAS Blood Plasma Derivatives Product Portfolio
  42. 7.7.5 RAAS Recent Developments
  43. 7.8 Nanyue Bio
  44. 7.8.1 Nanyue Bio Company Information
  45. 7.8.2 Nanyue Bio Business Overview
  46. 7.8.3 Nanyue Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Nanyue Bio Blood Plasma Derivatives Product Portfolio
  48. 7.8.5 Nanyue Bio Recent Developments
  49. 7.9 Hualan Bio
  50. 7.9.1 Hualan Bio Company Information
  51. 7.9.2 Hualan Bio Business Overview
  52. 7.9.3 Hualan Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hualan Bio Blood Plasma Derivatives Product Portfolio
  54. 7.9.5 Hualan Bio Recent Developments
  55. 7.10 Boya Bio
  56. 7.10.1 Boya Bio Company Information
  57. 7.10.2 Boya Bio Business Overview
  58. 7.10.3 Boya Bio Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Boya Bio Blood Plasma Derivatives Product Portfolio
  60. 7.10.5 Boya Bio Recent Developments
  61. 7.11 Octapharma
  62. 7.11.1 Octapharma Company Information
  63. 7.11.2 Octapharma Business Overview
  64. 7.11.3 Octapharma Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Octapharma Blood Plasma Derivatives Product Portfolio
  66. 7.11.5 Octapharma Recent Developments
  67. 7.12 LFB Group
  68. 7.12.1 LFB Group Company Information
  69. 7.12.2 LFB Group Business Overview
  70. 7.12.3 LFB Group Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  71. 7.12.4 LFB Group Blood Plasma Derivatives Product Portfolio
  72. 7.12.5 LFB Group Recent Developments
  73. 7.13 KM Biologics
  74. 7.13.1 KM Biologics Company Information
  75. 7.13.2 KM Biologics Business Overview
  76. 7.13.3 KM Biologics Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  77. 7.13.4 KM Biologics Blood Plasma Derivatives Product Portfolio
  78. 7.13.5 KM Biologics Recent Developments
  79. 7.14 Kedrion
  80. 7.14.1 Kedrion Company Information
  81. 7.14.2 Kedrion Business Overview
  82. 7.14.3 Kedrion Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Kedrion Blood Plasma Derivatives Product Portfolio
  84. 7.14.5 Kedrion Recent Developments
  85. 7.15 Grifols
  86. 7.15.1 Grifols Company Information
  87. 7.15.2 Grifols Business Overview
  88. 7.15.3 Grifols Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Grifols Blood Plasma Derivatives Product Portfolio
  90. 7.15.5 Grifols Recent Developments
  91. 7.16 CSL
  92. 7.16.1 CSL Company Information
  93. 7.16.2 CSL Business Overview
  94. 7.16.3 CSL Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  95. 7.16.4 CSL Blood Plasma Derivatives Product Portfolio
  96. 7.16.5 CSL Recent Developments
  97. 7.17 BPL
  98. 7.17.1 BPL Company Information
  99. 7.17.2 BPL Business Overview
  100. 7.17.3 BPL Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  101. 7.17.4 BPL Blood Plasma Derivatives Product Portfolio
  102. 7.17.5 BPL Recent Developments
  103. 7.18 Biotest
  104. 7.18.1 Biotest Company Information
  105. 7.18.2 Biotest Business Overview
  106. 7.18.3 Biotest Blood Plasma Derivatives Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Biotest Blood Plasma Derivatives Product Portfolio
  108. 7.18.5 Biotest Recent Developments
8 North America
  1. 8.1 North America Blood Plasma Derivatives Revenue (2021-2032)
  2. 8.2 North America Blood Plasma Derivatives Revenue by Type (2021-2032)
  3. 8.2.1 North America Blood Plasma Derivatives Revenue by Type (2021-2026)
  4. 8.2.2 North America Blood Plasma Derivatives Revenue by Type (2027-2032)
  5. 8.3 North America Blood Plasma Derivatives Revenue Share by Type (2021-2032)
  6. 8.4 North America Blood Plasma Derivatives Revenue by Application (2021-2032)
  7. 8.4.1 North America Blood Plasma Derivatives Revenue by Application (2021-2026)
  8. 8.4.2 North America Blood Plasma Derivatives Revenue by Application (2027-2032)
  9. 8.5 North America Blood Plasma Derivatives Revenue Share by Application (2021-2032)
  10. 8.6 North America Blood Plasma Derivatives Revenue by Country
  11. 8.6.1 North America Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Blood Plasma Derivatives Revenue by Country (2021-2026)
  13. 8.6.3 North America Blood Plasma Derivatives Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Blood Plasma Derivatives Revenue (2021-2032)
  2. 9.2 Europe Blood Plasma Derivatives Revenue by Type (2021-2032)
  3. 9.2.1 Europe Blood Plasma Derivatives Revenue by Type (2021-2026)
  4. 9.2.2 Europe Blood Plasma Derivatives Revenue by Type (2027-2032)
  5. 9.3 Europe Blood Plasma Derivatives Revenue Share by Type (2021-2032)
  6. 9.4 Europe Blood Plasma Derivatives Revenue by Application (2021-2032)
  7. 9.4.1 Europe Blood Plasma Derivatives Revenue by Application (2021-2026)
  8. 9.4.2 Europe Blood Plasma Derivatives Revenue by Application (2027-2032)
  9. 9.5 Europe Blood Plasma Derivatives Revenue Share by Application (2021-2032)
  10. 9.6 Europe Blood Plasma Derivatives Revenue by Country
  11. 9.6.1 Europe Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Blood Plasma Derivatives Revenue by Country (2021-2026)
  13. 9.6.3 Europe Blood Plasma Derivatives Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Blood Plasma Derivatives Revenue (2021-2032)
  2. 10.2 China Blood Plasma Derivatives Revenue by Type (2021-2032)
  3. 10.2.1 China Blood Plasma Derivatives Revenue by Type (2021-2026)
  4. 10.2.2 China Blood Plasma Derivatives Revenue by Type (2027-2032)
  5. 10.3 China Blood Plasma Derivatives Revenue Share by Type (2021-2032)
  6. 10.4 China Blood Plasma Derivatives Revenue by Application (2021-2032)
  7. 10.4.1 China Blood Plasma Derivatives Revenue by Application (2021-2026)
  8. 10.4.2 China Blood Plasma Derivatives Revenue by Application (2027-2032)
  9. 10.5 China Blood Plasma Derivatives Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Blood Plasma Derivatives Revenue (2021-2032)
  2. 11.2 Asia Blood Plasma Derivatives Revenue by Type (2021-2032)
  3. 11.2.1 Asia Blood Plasma Derivatives Revenue by Type (2021-2026)
  4. 11.2.2 Asia Blood Plasma Derivatives Revenue by Type (2027-2032)
  5. 11.3 Asia Blood Plasma Derivatives Revenue Share by Type (2021-2032)
  6. 11.4 Asia Blood Plasma Derivatives Revenue by Application (2021-2032)
  7. 11.4.1 Asia Blood Plasma Derivatives Revenue by Application (2021-2026)
  8. 11.4.2 Asia Blood Plasma Derivatives Revenue by Application (2027-2032)
  9. 11.5 Asia Blood Plasma Derivatives Revenue Share by Application (2021-2032)
  10. 11.6 Asia Blood Plasma Derivatives Revenue by Country
  11. 11.6.1 Asia Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Blood Plasma Derivatives Revenue by Country (2021-2026)
  13. 11.6.3 Asia Blood Plasma Derivatives Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Blood Plasma Derivatives Revenue (2021-2032)
  2. 12.2 SAMEA Blood Plasma Derivatives Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Blood Plasma Derivatives Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Blood Plasma Derivatives Revenue by Type (2027-2032)
  5. 12.3 SAMEA Blood Plasma Derivatives Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Blood Plasma Derivatives Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Blood Plasma Derivatives Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Blood Plasma Derivatives Revenue by Application (2027-2032)
  9. 12.5 SAMEA Blood Plasma Derivatives Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Blood Plasma Derivatives Revenue by Country
  11. 12.6.1 SAMEA Blood Plasma Derivatives Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Blood Plasma Derivatives Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Blood Plasma Derivatives Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst